BackgroundCheck.run
Search For

Monica A Goldberg Deceased1880 Strasburg Rd, Romansville, PA 19320

Monica Goldberg Phones & Addresses

1880 Strasburg Rd, Coatesville, PA 19320    610-4860503    610-4860506   

3 Stanford Rd, Somers Point, NJ 08244    610-4860506   

Philadelphia, PA   

Chester, PA   

Mentions for Monica A Goldberg

Monica Goldberg resumes & CV records

Resumes

Monica Goldberg Photo 19

Founder

Work:
Essential
Founder
Monica Goldberg Photo 20

Monica Goldberg

Monica Goldberg Photo 21

Monica Goldberg

Publications & IP owners

Us Patents

Humanized Anti-Cd134 (Ox40) Antibodies And Uses Thereof

US Patent:
2017036, Dec 28, 2017
Filed:
Sep 11, 2017
Appl. No.:
15/700986
Inventors:
- GJ Almere, NL
- Titusville NJ, US
Jinquan LUO - Spring House PA, US
Randall BREZSKI - Spring House PA, US
Monica GOLDBERG - Spring House PA, US
International Classification:
C07K 16/30
C07K 16/28
Abstract:
The invention provides antibodies that specifically bind to human CD134. Anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Humanized anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.

Humanized Anti-Cd134 (Ox40) Antibodies And Uses Thereof

US Patent:
2014037, Dec 25, 2014
Filed:
Mar 20, 2014
Appl. No.:
14/221212
Inventors:
- Titusville NJ, US
- Utrecht, NL
Jinquan LUO - Spring House PA, US
Randall BREZSKI - Spring House PA, US
Monica GOLDBERG - Spring House PA, US
Assignee:
JANSSEN PHARMACEUTICALS, INC. - Titusville NJ
BIOCEROX PRODUCTS B.V. - Utrecht
International Classification:
C07K 16/30
US Classification:
4241741, 5303897, 536 2353, 4353201, 5303873, 435334
Abstract:
The invention provides antibodies that specifically bind to human CD134. Anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Humanized anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.